Cargando…

Rhus Coriaria L. (Sumac) in Patients with Hyperlipidemia; A Double Blind Randomized Clinical Trial

BACKGROUND: Lipid lowering effect of sumac is investigated in multiple animal studies with promising results. However, its clinical efficacy is not investigated adequately. This study is aimed to evaluate the lipid lowering effect of sumac in patients with Hyperlipidemia in a double blind randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajmohammadi, Zahra, Shams, Mesbah, Zibainejad, Mohammad Javad, Nimrouzi, Majid, Fardidi, Pouya, Heydari, Mojtaba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Journal of Medical Sciences 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103515/
https://www.ncbi.nlm.nih.gov/pubmed/27840476
_version_ 1782466608811212800
author Hajmohammadi, Zahra
Shams, Mesbah
Zibainejad, Mohammad Javad
Nimrouzi, Majid
Fardidi, Pouya
Heydari, Mojtaba
author_facet Hajmohammadi, Zahra
Shams, Mesbah
Zibainejad, Mohammad Javad
Nimrouzi, Majid
Fardidi, Pouya
Heydari, Mojtaba
author_sort Hajmohammadi, Zahra
collection PubMed
description BACKGROUND: Lipid lowering effect of sumac is investigated in multiple animal studies with promising results. However, its clinical efficacy is not investigated adequately. This study is aimed to evaluate the lipid lowering effect of sumac in patients with Hyperlipidemia in a double blind randomized controlled trial. METHODS: Eighty patients with Hyperlipidemia according to NCEP-ATP III criteria were randomly allocated to receive the Rhus Coriaria L. (1000 mg/day) or placebo for two months. The patients were evaluated in terms of the serum triglyceride, total LDL, and HDL cholesterol. Systolic and diastolic blood pressures along with serum biochemistry profile including fasting blood sugar, liver and kidney function tests and complete blood count were evaluated before the enrolment of patients and after the intervention. RESULTS: No significant difference was observed between the sumac and placebo groups in term of mean reductions in total and LDL cholesterol and triglyceride levels. A significant increase in mean serum HDL cholesterol level was observed in the sumac group (41.18±8.2 vs. 44.65±8.4, P=0.001) after 2 months of intervention. CONCLUSION: The study showed significant HDL cholesterol increasing effect of sumac supplementation in patients with Hyperlipidemia.
format Online
Article
Text
id pubmed-5103515
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Iranian Journal of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-51035152016-11-11 Rhus Coriaria L. (Sumac) in Patients with Hyperlipidemia; A Double Blind Randomized Clinical Trial Hajmohammadi, Zahra Shams, Mesbah Zibainejad, Mohammad Javad Nimrouzi, Majid Fardidi, Pouya Heydari, Mojtaba Iran J Med Sci Oral BACKGROUND: Lipid lowering effect of sumac is investigated in multiple animal studies with promising results. However, its clinical efficacy is not investigated adequately. This study is aimed to evaluate the lipid lowering effect of sumac in patients with Hyperlipidemia in a double blind randomized controlled trial. METHODS: Eighty patients with Hyperlipidemia according to NCEP-ATP III criteria were randomly allocated to receive the Rhus Coriaria L. (1000 mg/day) or placebo for two months. The patients were evaluated in terms of the serum triglyceride, total LDL, and HDL cholesterol. Systolic and diastolic blood pressures along with serum biochemistry profile including fasting blood sugar, liver and kidney function tests and complete blood count were evaluated before the enrolment of patients and after the intervention. RESULTS: No significant difference was observed between the sumac and placebo groups in term of mean reductions in total and LDL cholesterol and triglyceride levels. A significant increase in mean serum HDL cholesterol level was observed in the sumac group (41.18±8.2 vs. 44.65±8.4, P=0.001) after 2 months of intervention. CONCLUSION: The study showed significant HDL cholesterol increasing effect of sumac supplementation in patients with Hyperlipidemia. Iranian Journal of Medical Sciences 2016-05 /pmc/articles/PMC5103515/ /pubmed/27840476 Text en Copyright: © Iranian Journal of Medical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Oral
Hajmohammadi, Zahra
Shams, Mesbah
Zibainejad, Mohammad Javad
Nimrouzi, Majid
Fardidi, Pouya
Heydari, Mojtaba
Rhus Coriaria L. (Sumac) in Patients with Hyperlipidemia; A Double Blind Randomized Clinical Trial
title Rhus Coriaria L. (Sumac) in Patients with Hyperlipidemia; A Double Blind Randomized Clinical Trial
title_full Rhus Coriaria L. (Sumac) in Patients with Hyperlipidemia; A Double Blind Randomized Clinical Trial
title_fullStr Rhus Coriaria L. (Sumac) in Patients with Hyperlipidemia; A Double Blind Randomized Clinical Trial
title_full_unstemmed Rhus Coriaria L. (Sumac) in Patients with Hyperlipidemia; A Double Blind Randomized Clinical Trial
title_short Rhus Coriaria L. (Sumac) in Patients with Hyperlipidemia; A Double Blind Randomized Clinical Trial
title_sort rhus coriaria l. (sumac) in patients with hyperlipidemia; a double blind randomized clinical trial
topic Oral
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103515/
https://www.ncbi.nlm.nih.gov/pubmed/27840476
work_keys_str_mv AT hajmohammadizahra rhuscoriarialsumacinpatientswithhyperlipidemiaadoubleblindrandomizedclinicaltrial
AT shamsmesbah rhuscoriarialsumacinpatientswithhyperlipidemiaadoubleblindrandomizedclinicaltrial
AT zibainejadmohammadjavad rhuscoriarialsumacinpatientswithhyperlipidemiaadoubleblindrandomizedclinicaltrial
AT nimrouzimajid rhuscoriarialsumacinpatientswithhyperlipidemiaadoubleblindrandomizedclinicaltrial
AT fardidipouya rhuscoriarialsumacinpatientswithhyperlipidemiaadoubleblindrandomizedclinicaltrial
AT heydarimojtaba rhuscoriarialsumacinpatientswithhyperlipidemiaadoubleblindrandomizedclinicaltrial